OGN

Organon & Co. (OGN) | Rumor.io

Organon

OGN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,302

Bullish sentiment (50-day avg)100%

Price to earnings ratio17.6

Market capitalization3.6B

Earnings per share0.78

Dividend yield (TTM)0.58%

Revenue (annual)6.2B

Net income (annual)187M

Social

What share of all stock conversation is about OGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Jul 4

Organon & Co.'s stock has been mentioned as potentially making a move similar to another asset, and it has rebounded from a low, with some analysts expecting a potential dip or a breakout.
The company's stock has seen a significant increase in price, with some users noting a profit of over 1,700% and others expecting a potential short squeeze.
Some analysts have identified an ascending channel on the company's stock, while others have noted a potential breakdown and are shorting the asset.

Generated by AI

Sentiment

Of the messages about OGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.72% +5.14
Bearish	—	—	—	3.28% -5.14

Bullish· Apr 29

Organon & Co. ($OGN) has achieved significant revenue growth from $27.8M to $81.8M, indicating rapid scaling within the NXXT system.
The company's recent Q4 results of $22.9M confirm stable execution across NXXT operations, demonstrating continued strength in the system.
$OGN's Q4 performance is a positive indicator for the company's future prospects, with its chart improving after a strong move and follow-through momentum building.

Bearish· Apr 10

$OGN's valuation is 2B with heavy debt maturing in the next 8 months, making a 12B bid from India financially nonsensical.
Sun Pharma's 4% drop after a 12B bid for $OGN raises debt worries despite strong cash and ongoing deal talks.
$OGN's price is drifting lower, still below its previous top, and may be a short opportunity due to potential pump and dump activity.

Generated by AI

Topics

Of the messages about OGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	17.9%
Technical Analysis	—	—	0%	0.18%
Analysts	—	—	0%	0.62%
Controversies	—	—	0%	0.06%
Earnings	—	—	0%	0.74%
Macro	—	—	0%	80.49%

Announcements· May 18

Organon & Co. has executed buybacks of $OGN, with the most recent purchase being 102,004 $OGN.
The company's staking APY is now at 14.65%.
Buybacks this past month have ranged from $138,261 to $177,678.

Technical Analysis· Apr 27

OGN's follow-through will confirm the trend if it continues.
A pullback strategy caught the low in OGN last week, and is available for student education.
OGN closed a marubozu on the 15m, with no upper wick and a clean move down, indicating a strong bearish signal.

Generated by AI

Community

Of the messages about OGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	10%	2.12%
Newcomers	—	—	90%	97.88%

Regulars· Apr 27

Organon stockholders will receive $14.00 per share in cash, valuing the company at an enterprise value of $11.75 billion.
The acquisition is a 24% premium to Organon's current market price, and represents a significant expansion into biosimilars and women's health for Sun Pharmaceutical Industries.
The deal price of $14.00 per share is 63% lower than Organon's spin-off price from Merck just five years ago, raising questions about value destruction, failure, and the potential for regulatory hurdles.

Newcomers· May 1

The $120 million payment from Organon to Sun Pharma is a significant deal that could impact the company's financials.
Newcomers are focusing on Organon's potential for growth due to its exploration story, with early-stage assets aligning with macro demand.
Organon's focus on pre-production exploration could create value early, with shallow drilling leaving deeper zones open for potential upside.

Generated by AI

Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

7d agoYahoo Finance

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

8d agoYahoo Finance

how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com

13d agoInvesting.com

Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review

Organon (OGN) said Monday the US Food and Drug Administration has accepted for review a supplemental

16d agoYahoo Finance

Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)

18d agoSeeking Alpha

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

21d agoYahoo Finance

Also Discussed

Investors talking about OGN also mention

#	Name	Attention
1	United Natural Foods Inc.UNFI	0%new
2	Cheer Holding, Inc. Class A Ordinary ShareCHR	0%0
3	Entergy New Orleans LLC Preferred Stock 5%ENJ	0%new
4	AKRO - Akero Therapeutics, Inc.	——
5	PNT - POINT Biopharma Global Inc.	——
6	Band ProtocolBAND	0%new
7	TD SYNNEX CorporationSNX	0%0
8	Medtronic plcMDT	0%+0
9	OntologyONT	0%0
10	Mirion Technologies, Inc. Class A Common StockMIR	0%0

Organon & Co.

Healthcare
Drug Manufacturers - General

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.

Website

Location

30 Hudson Street

Jersey City, NJ, 07302

United States

Social

What share of all stock conversation is about OGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Jul 4

Organon & Co.'s stock has been mentioned as potentially making a move similar to another asset, and it has rebounded from a low, with some analysts expecting a potential dip or a breakout.
The company's stock has seen a significant increase in price, with some users noting a profit of over 1,700% and others expecting a potential short squeeze.
Some analysts have identified an ascending channel on the company's stock, while others have noted a potential breakdown and are shorting the asset.

Generated by AI

Sentiment

Of the messages about OGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.72% +5.14
Bearish	—	—	—	3.28% -5.14

Bullish· Apr 29

Organon & Co. ($OGN) has achieved significant revenue growth from $27.8M to $81.8M, indicating rapid scaling within the NXXT system.
The company's recent Q4 results of $22.9M confirm stable execution across NXXT operations, demonstrating continued strength in the system.
$OGN's Q4 performance is a positive indicator for the company's future prospects, with its chart improving after a strong move and follow-through momentum building.

Bearish· Apr 10

$OGN's valuation is 2B with heavy debt maturing in the next 8 months, making a 12B bid from India financially nonsensical.
Sun Pharma's 4% drop after a 12B bid for $OGN raises debt worries despite strong cash and ongoing deal talks.
$OGN's price is drifting lower, still below its previous top, and may be a short opportunity due to potential pump and dump activity.

Generated by AI

Topics

Of the messages about OGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	17.9%
Technical Analysis	—	—	0%	0.18%
Analysts	—	—	0%	0.62%
Controversies	—	—	0%	0.06%
Earnings	—	—	0%	0.74%
Macro	—	—	0%	80.49%

Announcements· May 18

Organon & Co. has executed buybacks of $OGN, with the most recent purchase being 102,004 $OGN.
The company's staking APY is now at 14.65%.
Buybacks this past month have ranged from $138,261 to $177,678.

Technical Analysis· Apr 27

OGN's follow-through will confirm the trend if it continues.
A pullback strategy caught the low in OGN last week, and is available for student education.
OGN closed a marubozu on the 15m, with no upper wick and a clean move down, indicating a strong bearish signal.

Generated by AI

Community

Of the messages about OGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	10%	2.12%
Newcomers	—	—	90%	97.88%

Regulars· Apr 27

Organon stockholders will receive $14.00 per share in cash, valuing the company at an enterprise value of $11.75 billion.
The acquisition is a 24% premium to Organon's current market price, and represents a significant expansion into biosimilars and women's health for Sun Pharmaceutical Industries.
The deal price of $14.00 per share is 63% lower than Organon's spin-off price from Merck just five years ago, raising questions about value destruction, failure, and the potential for regulatory hurdles.

Newcomers· May 1

The $120 million payment from Organon to Sun Pharma is a significant deal that could impact the company's financials.
Newcomers are focusing on Organon's potential for growth due to its exploration story, with early-stage assets aligning with macro demand.
Organon's focus on pre-production exploration could create value early, with shallow drilling leaving deeper zones open for potential upside.

Generated by AI

Organon

Social

Jul 4

Bullish· Apr 29

Bearish· Apr 10

Announcements· May 18

Technical Analysis· Apr 27

Regulars· Apr 27

Newcomers· May 1

Why Organon (OGN) Is Getting Attention Today

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com

Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review

Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

Organon & Co.

Company Information

Location

Why Organon (OGN) Is Getting Attention Today

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com

Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review

Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

Social

Jul 4

Bullish· Apr 29

Bearish· Apr 10

Announcements· May 18

Technical Analysis· Apr 27

Regulars· Apr 27

Newcomers· May 1